17-7669692-T-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000546.6(TP53):c.1101-2A>G variant causes a splice acceptor, intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000546.6 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Li-Fraumeni syndrome 1 Pathogenic:2
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
- -
Hereditary cancer-predisposing syndrome Pathogenic:2
- -
The c.1101-2A>G intronic variant results from a A to G substitution two nucleotides before coding exon 10 of the TP53 gene. This alteration was identified in a 2 year-old Asian child with adrenocortical tumor by one study. The same study conducted an analysis of the tumor tissue, demonstrating loss of heterozygosity and the utilization of an alternative acceptor site leading to a frameshift and alternate termination of the resulting protein (Pinto E et al Fam Cancer. 2011 Mar;10(1):141-6). This alteration was also identified in 1/10030 consecutive patients referred for evaluation by an NGS hereditary cancer panel, in a proband with breast cancer (Susswein et al. Genet. Med. 2016 Aug;18(8):823-32). However, this alteration has also been observed in several individuals with TP53-related cancers, but not meeting classic LFS or Chompret criteria (Ambry internal data). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site; however, direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. -
not provided Pathogenic:1Other:1
- -
Canonical splice site variant predicted to result in an in-frame loss of the adjacent exon in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 26681312, 22495821, 26205489, 20932800, 20967502, 34863587, 31105275) -
Li-Fraumeni syndrome Pathogenic:1
This sequence change affects an acceptor splice site in intron 10 of the TP53 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely disrupts the C-terminus of the protein. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with breast cancer or an adrenocortical tumor (PMID: 20967502, 26681312). This variant is also known as IVS10-2 A>G . ClinVar contains an entry for this variant (Variation ID: 141332). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that disruption of this splice site results in activation of a cryptic splice site and introduces a new termination codon (PMID: 20967502). However the mRNA is not expected to undergo nonsense-mediated decay. This variant disrupts the C-terminal domain of the TP53 protein, which is required for DNA binding and transactivation activity (PMID: 22178617, 25794615, 26205489). While functional studies have not been performed to directly test the effect of this variant on TP53 protein function, this suggests that disruption of this region of the protein is causative of disease. For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at